CYMABAY THERAPEUTICS
CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on the development and commercialization of proprietary new medicines for important human diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline. Arhalofenate is a novel oral s... mall molecule being developed to treat the approximately 1 million gout patients that flare three or more times per year. Gout flares are painful inflammatory episodes caused by crystals of monosodium urate (MSU) that result from excess serum uric acid (sUA). In three Phase 2 studies in gout patients arhalofenate was shown to reduce the incidence and duration of flares while simultaneously lowering sUA. If confirmed in additional clinical studies, arhalofenate’s dual acting profile would be unique since all other urate lowering therapies paradoxically increase flares as they lower sUA over the first 6 to 12 months of treatment. Increased flares lead many patients to stop or avoid treatment leading to progression of disease with pain and suffering, erosion of joint structure and functionality, lost time from work, and increased healthcare costs.
CYMABAY THERAPEUTICS
Social Links:
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
1991-01-01
Address:
Hayward, California, United States
Country:
United States
Website Url:
http://www.cymabay.com
Total Employee:
51+
Status:
Active
Contact:
5102938800
Email Addresses:
[email protected]
Total Funding:
366.51 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Universal Analytics Domain Not Resolving Apache
Similar Organizations
Acer Therapeutics
Acer Therapeutics focuses on the acquisition, development, and commercialization of therapies for patients with serious rare diseases.
Bexion Pharmaceuticals
Bexion Pharmaceuticals is a privately-held biotech company focused on the development and commercialization of innovative cures for cancer.
BioMarin Pharmaceutical
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.
Castle Creek Biosciences
Castle Creek Biosciences is focused on developing commercializing novel, personalized gene therapies for rare skin disorders.
CRISPR Therapeutics
CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform.
Cyteir Therapeutics
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.
Athenex
Athenex is a biopharmaceutical company that develops and discovers novel therapies for treating cancer and related conditions.
Lentigen
Lentigen Corporation is engaged in the development and commercialization of gene delivery technologies for human diseases.
Nirogy Therapeutics
Nirogy Therapeutics is focusing on small-molecule drugs that target the solute carrier family of transporter proteins (SLCTs).
PAREXEL
PAREXEL is a biopharmaceutical services company that focuses on the development and commercialization of new medical therapies worldwide.
Bambu Global
Bambu Global focuses on developing and commercializing breakthrough scientific discoveries.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Galectin Therapeutics
Galectin Therapeutics uses galectin science and drug development to create new therapies for fibrotic diseases and cancer.
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals specializes in the development and commercialization of ophthalmic products for the treatment of eye diseases.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Receptos
Receptos focuses on the discovery, development and commercialization of various therapeutics for immune disorders.
Revive Therapeutics
Revive Therapeutics is focused on the research, development and commercialization ofnovel therapies and technologies company.
Sorrento Therapeutics
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
Sunshine Biopharma
Sunshine Biopharma focuses on the research, development, and commercialization of drugs for the treatment of various forms of cancer.
Synta Pharmaceuticals
Synta Pharmaceuticals is focused on developing and commercializing small molecule drugs to treat cancer and chronic inflammatory diseases.
TargImmune Therapeutics
TargImmune Therapeutics is focused on drug development using novel targeted onco-immunotherapies.
ULURU
ULURU engages in the research, development, and commercialization of wound care and mucoadhesive film products.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Abingworth
Abingworth investment in Post-IPO Debt - CymaBay Therapeutics
Silicon Valley Bank
Silicon Valley Bank investment in Debt Financing - CymaBay Therapeutics
Oxford Finance LLC
Oxford Finance LLC investment in Debt Financing - CymaBay Therapeutics
Merlin Biomed
Merlin Biomed investment in Series E - CymaBay Therapeutics
Birchmere Ventures
Birchmere Ventures investment in Series E - CymaBay Therapeutics
Alta Partners
Alta Partners investment in Series E - CymaBay Therapeutics
KBC
KBC investment in Series E - CymaBay Therapeutics
Bay City Capital
Bay City Capital investment in Series E - CymaBay Therapeutics
Next Chapter Holdings
Next Chapter Holdings investment in Series E - CymaBay Therapeutics
Versant Ventures
Versant Ventures investment in Series E - CymaBay Therapeutics
Official Site Inspections
http://www.cymabay.com Semrush global rank: 3.02 M Semrush visits lastest month: 5.37 K
- Host name: ec2-174-129-30-187.compute-1.amazonaws.com
- IP address: 174.129.30.187
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "CymaBay Therapeutics" on Search Engine
Gilead Sciences Announces Completion of Acquisition of …
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay …See details»
Gilead Sciences Expands Liver Portfolio With Acquisition …
FOSTER CITY, Calif. & NEWARK, Calif.-- (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced today a …See details»
Gilead Sciences Announces Completion of Acquisition of CymaBay
FOSTER CITY, Calif., March 22, 2024 -- ( BUSINESS WIRE )--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced …See details»
Gilead Sciences Announces Completion of Acquisition of …
FOSTER CITY, Calif.-- (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay …See details»
CymaBay Therapeutics - Crunchbase Company Profile
CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on the development and commercialization of proprietary …See details»
CymaBay Therapeutics’ $4.3 Billion Acquisition by …
February 12, 2024. On February 12, 2024, CymaBay Therapeutics (“CymaBay”) and Gilead Sciences, Inc. (“Gilead”) announced a definitive agreement under which Gilead …See details»
Gilead Sciences Announces Completion of Acquisition of CymaBay
FOSTER CITY, CA – Gilead Sciences, Inc. (Nasdaq: GILD) announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: …See details»
Gilead Sciences Expands Liver Portfolio With Acquisition of …
FOSTER CITY, Calif. & NEWARK, Calif., February 12, 2024 -- ( BUSINESS WIRE )--Gilead Sciences, Inc. (Nasdaq: GILD) and CymaBay Therapeutics, Inc. (Nasdaq: CBAY) …See details»
UPDATE 2-Drugmaker Gilead to acquire CymaBay for $4.3 bln
Feb 12 (Reuters) - U.S. drugmaker Gilead Sciences agreed to acquire CymaBay Therapeutics for $4.3 billion on Monday, adding a treatment for chronic liver disease to …See details»
Gilead acquires CymaBay Therapeutics for $4.3bn
Gilead Sciences has concluded the acquisition of CymaBay Therapeutics for $4.3bn. The strategic move was finalised following the closure of a tender offer for the acquisition of …See details»
Investigational Seladelpar Demonstrates Significant …
About CymaBay. CymaBay Therapeutics Inc. was acquired by Gilead Sciences in March 2024. CymaBay Therapeutics, a Gilead Company, is a clinical-stage …See details»
CymaBay Therapeutics, Inc.
Organization and Description of Business CymaBay Therapeutics, Inc. (the Company or CymaBay) is a clinical-stage biopharmaceutical company focused on developing and …See details»
Investors & Media :: CymaBay Therapeutics (CBAY)
We are a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with liver and other chronic diseases with high unmet medical …See details»
CymaBay Therapeutics - Funding, Financials, Valuation & Investors
$854.2M. in funding over 16 rounds. Their latest funding was raised on Sep 11, 2023 from a Post-IPO Equity round. CymaBay Therapeutics is registered under the ticker …See details»
Gilead liver disease med still delivers ahead of FDA verdict
Three months after spending $4.3 billion on CymaBay Therapeutics for its primary biliary cholangitis (PBC) med, Gilead Sciences has presented a fresh slice of data as a …See details»
CymaBay Therapeutics - Contacts, Employees, Board Members, …
CymaBay Therapeutics. Connect to CRM. Summary Financials People Technology Signals & News Similar Companies. Highlights. Employee Profiles 11. Number of Board …See details»
CymaBay Therapeutics announces departure of chief commercial …
CymaBay Therapeutics ( NASDAQ: CBAY) disclosed on Thursday that chief commercial officer Lewis Stuart will step down effective December 29. Ben Kozub, VP Liver …See details»
CymaBay Announces Closing of Upsized $258.7 Million Public …
NEWARK, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing …See details»
CymaBay Therapeutics (CBAY) Earnings Date and Reports 2024 …
CymaBay Therapeutics last posted its quarterly earnings data on February 28th, 2024. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the …See details»
Leadership Team :: CymaBay Therapeutics (CBAY)
Leadership Team :: CymaBay Therapeutics (CBAY) Overview. News & Events. Company Info. Financial Info. SEC Filings. Sujal Shah. President and Chief Executive Officer. Mr. …See details»